See every side of every news story
Get Started
SubscribeLogin
Israel-Hamas Conflict
Eurovision
Social Media
Soccer
European Union
Instagram
Donald Trump
Premier League
Manchester United
Vladimir Putin
Baseball
Pope Francis
Natural Disasters
Published • loading... • Updated

Pembrolizumab/Lenvatinib Elicits Responses in HGSOC

Summary by targetedonc.com
The combination of pembrolizumab and lenvatinib led to encouraging clinical activity in patients with platinum-resistant high-grade serous ovarian cancer.
DisclaimerThis story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.

1 Articles

All
Left
Center
Right
targetedonc.comtargetedonc.com

Pembrolizumab/Lenvatinib Elicits Responses in HGSOC

The combination of pembrolizumab and lenvatinib led to encouraging clinical activity in patients with platinum-resistant high-grade serous ovarian cancer.

Read Full Article
Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe

Bias Distribution

  • There is no tracked Bias information for the sources covering this story.
Factuality

To view factuality data please Upgrade to Premium

Ownership

To view ownership data please Upgrade to Vantage

targetedonc.com broke the news in on Friday, May 16, 2025.
Sources are mostly out of (0)
Stories disproportionately reported by the Left or the Right

Similar News Topics

News
For You
SearchBlindspotLocal